loader
report-image

Non-Insulin Therapies for Diabetes Market Size - By Type(Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration(Oral, Intramuscular), by Distribution Channel(Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) & Region - Forecasts 2023 -2033

  • PUBLISHED ON
  • 2022-08-04
  • NO OF PAGES
  • 225
  • CATEGORY
  • Healthcare & Life Sciences

Non-Insulin Therapies for Diabetes Market: Description

Non-insulin therapies are normally used in type 2 diabetes patients, where body either doesn't convey sufficient insulin or can't effectively use the insulin it produces. Non-insulin-based drug works with different arrangement of activities to reduce blood glucose level and maintain ideal glycaemic control. For instance, a couple of administrators increase the insulin release from pancreatic cells (Sulfonylureas), whereas certain experts increase glucose take-up by periphery and diminishes hepatic glucose yield (Biguanides), On the other hand, many administrators prevent absorption of starch in small gastrointestinal system (alpha glucosidase inhibitors), and some solutions diminish post supper sugar by hindering specific chemical.


IMG1

Source: WMR


Non-Insulin Therapies for Diabetes Market: Overview

The Non-Insulin Therapies for Diabetes Market size was $ 61.090.1 million in 2022, and is anticipated to increase to a worth of more than $ 105,461.5 million by 2033, registering a CAGR (compound annual growth rate) of over 6% from 2023 to 2033.

The main considerations driving the development of the market is the rapid expansion in the quantity of individuals impacted by Diabetes Type 2. The engagement of organizations to produce drugs with less incidental effects has contributed a ton to the development of the market. Non-insulin drugs, when infused into the body, assists the liver to produce insulin. Although, the insulin market ruled previously, but these kind of the non-insulin drug will soon be at a similar level as insulin type drugs. The change is way of life and food habits are the reason for diabetes, and along these lines, they will push forward market progression.

The key challenge for this market is to produce drugs that have less aftereffects and more efficient than the currently utilized drugs. The advantages of these medications are still unknown to many, so less awareness is likewise a challenge. The accessibility of these medications to all sections of the population is additionally a major challenge as diabetes is a typical disease. The overall awareness about the functions and employments of these medications is not known to many, so increasing the cognizance level of the individuals is another challenge for this market. The public authority drives about spreading awareness among these masses on the function and availability of these drugs are not on a large scale and in this way limit the development of the market.


IMG2

Source: WMR



 

Non-Insulin Therapies for Diabetes Market: Key trends

·         Developing Prevalence of Non-Invasive Treatments to Dive the Growth

Growing overall rate and preponderance of diabetes is depended upon to fuel advancement of the non-insulin treatment for diabetes promote. Non-insulin treatment is prevalently used in type 2 diabetes, which addresses a huge share of the overall diabetes cases. As demonstrated by the International Diabetes Federation's (IDF) Diabetes Atlas 2017, generally frequency of diabetic patients was more than 400 million, of which larger part were encountering type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the super three reasons behind death among non-infectious diseases globally. This is the main consideration that supports the expansion of worldwide non-insulin therapies for diabetes market.


·         New Product Launches to Boost the Growth

Healthcare companies and related organizations are launching and approving new products and treatments in the market, which is depended upon to drive increment of the overall non-insulin treatment for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) avowed Novo Nordisk's Ozempic, which is before seven days GLP-1 simple, would assemble the patient consistence. In December 2017, FDA insisted ertugliflozin made by the Merck and Co. additionally, Pfizer Inc. similarly, in January 2018, the European Medicines Agency (EMA) permitted support for the equivalent in Europe.


Non-Insulin Therapies for Diabetes Market: Segment Analysis

Non-Insulin Therapies for Diabetes Market based on Drug type

·         Sulphonylureas

·         Biguanides

·         Thiazolidinediones

·         Alpha-Glucosidase Inhibitors

·         Dipeptidyl Peptidase-4 (DPP4) Inhibitors

·         Type_ GLP-1 Analogs

·         Sodium-glucose co-transporter-2 (SGLT2) inhibitors

The Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor's segment is likely to observe vigorous development during the esteemed time frame in view of the drug type. The main reason adding to this segmental growth can be credited to the high efficacy of thus drug as it can be used both as monotherapy or combination treatment.

 

Non-Insulin Therapies for Diabetes Market based on route of administration

·         Oral

·         Intramuscular

IMG3

Source: WMR

Non-Insulin Therapies for Diabetes Market based on distribution channel

·         Retail Pharmacy

·         Hospital Pharmacy

·         Online Pharmacy


Non-Insulin Therapies for Diabetes Market - Geographical ambit

In term of geographic region, the non-insulin therapies for diabetes market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America had the biggest share in 2020 and is relied upon to develop with a healthy rate during the projected timeline. The rising prevalence of diabetes is the essential component supporting the development rate. The other factors impelling the market are numerous ongoing clinical preliminaries and the accessibility of further develop treatment choices and healthcare infrastructure. The presence of worldwide players will influence the market emphatically.


Non-Insulin Therapies for Diabetes Market: Competitive Landscape

The major players operating in the marketplace are AstraZeneca, Boehiringer Ingelheim GmbH, Bristol-Myers Squibb, Eli, Lilly and Company, GlaxoSmithKline, F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, GSK, Intarcia Therapeutics, Jiangsu Hansoh Pharmaceutical, Emisphere, Uni-Bio Science Group, Takeda Pharmaceuticals, and Others. 

To endure the cutthroat and divided nature of the global non-insulin therapies for diabetes market, players are taking on methodologies like partnership, joint efforts, and consolidations. These techniques permit the players to extend their business at a worldwide level. Furthermore, with these methodologies, the associations can reach to the undiscovered regions that can be worthwhile for the business. These methodologies likewise permit the organizations to secure assets that can additionally add to their manageability and achievement in the worldwide non-insulin therapies for diabetes market.

On the other side, recognized players are fusing trend setting innovations in their items. These innovations can foresee, monitor, and adjust according the utilization. These mechanical improvements give the producers a strategic advantage over their opponents that further assist them with having a fortification over the global non-insulin therapies for diabetes market.


Report Scope:

Non-Insulin Therapies for Diabetes Market Forecast Years: 2023-2033

Non-Insulin Therapies for Diabetes Market Historical Years: 2020-2021

Non-Insulin Therapies for Diabetes Market 2022: $61.090.1 million

Non-Insulin Therapies for Diabetes Market 2033: $105,461.5 million

Non-Insulin Therapies for Diabetes Market CAGR: 6%

Key Segments: Drug type, and geographic region.


Key Regions & Countries: North America (the United States, Canada, and Mexico), Europe, (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), and The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa).


Key Players: AstraZeneca, Boehiringer Ingelheim GmbH, Bristol-Myers Squibb, Eli, Lilly and Company, GlaxoSmithKline, F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, GSK, Intarcia Therapeutics, Jiangsu Hansoh Pharmaceutical, Emisphere, Uni-Bio Science Group, Takeda Pharmaceuticals, and Others. 

1. Global Non-Insulin Therapies for Diabetes Market Introduction and Market Overview

1.1. Objective of the Market Research Study

1.2. Non-Insulin Therapies for Diabetes Market Definition & Description

1.3. Research Data Parameters & Reporting Timelines

1.3.1. Historical Data Reporting Years – 2020 to 2021

1.3.2. Projected Data Reporting Years – 2022 to 2033

1.3.3. Reporting Data Parameters – Value (US$ Million)

1.4. Global Non-Insulin Therapies for Diabetes Market Scope and Market Estimation

1.4.1. Global Non-Insulin Therapies for Diabetes Overall Market Size (US$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)

1.4.2. Global Non-Insulin Therapies for Diabetes Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033

1.5. Non-Insulin Therapies for Diabetes Market Segmentation

1.5.1. Type of Global Non-Insulin Therapies for Diabetes Market

1.5.2. Route of Administration of Global Non-Insulin Therapies for Diabetes Market

1.5.3. Distribution Channel of Global Non-Insulin Therapies for Diabetes Market

1.5.4. Key Regions of Global Non-Insulin Therapies for Diabetes Market


2. Global Non-Insulin Therapies for Diabetes Market - Executive Summary

2.1. Global Non-Insulin Therapies for Diabetes Market – Summary & Snapshot

2.2. Global Non-Insulin Therapies for Diabetes Market, By Type (US$ Million)

2.3. Global Non-Insulin Therapies for Diabetes Market, By Route of Administration (US$ Million)

2.4. Global Non-Insulin Therapies for Diabetes Market, By Distribution Channel (US$ Million)

2.5. Global Non-Insulin Therapies for Diabetes Market, By Geography (US$ Million)

2.6. Global Non-Insulin Therapies for Diabetes Market Outlook & Future Opportunities


3. Non-Insulin Therapies for Diabetes Market Trends, Outlook, and Factors Analysis

3.1. Global Non-Insulin Therapies for Diabetes Market Industry Development Trends under COVID-19 Outbreak

3.1.1. Global COVID-19 Status Overview

3.1.2. Influence of COVID-19 Outbreak on Global Non-Insulin Therapies for Diabetes Market Industry Development

3.1.3. Pre & Post COVID-19 Trends and Scenarios

3.2. Non-Insulin Therapies for Diabetes Market Dynamics (Growth Impacting Factors & Rationales)

3.2.1. Drivers

3.2.1.1. Non-insulin-based medication helps in different mechanism such as reduce blood glucose level and maintain it for optimum glycemic control, these usage has been driving the market.

3.2.1.2. Driver 2

3.2.1.3. Driver 3

3.2.2. Restraints

3.2.2.1. Non-insulin based drugs of some class are high enough for everyone to afford it.

3.2.2.2. Restraint 2

3.2.3. Opportunities

3.2.3.1. New class of Non-insulin based drugs are being developed by various market players to with stand the market and have their share.

3.2.3.2. Opportunity 2

3.2.3.3. Opportunity 3

3.2.4. Impact Analysis of Drivers and Restraints

3.3. Ecosystem/ Value Chain Analysis

3.4. Porter’s Five Forces Analysis

3.5. SWOT Analysis

3.6. PEST Analysis

3.7. Average Selling Prices and Pricing Trends Analysis of Non-Insulin Therapies for Diabetes Market

3.8. Technological Roadmap

3.9. Key Investment Pockets of Non-Insulin Therapies for Diabetes Market

3.9.1. By Type

3.9.2. By Route of Administration

3.9.3. By Distribution Channel

3.9.4. By Regions


4. Global Non-Insulin Therapies for Diabetes Market: Estimates & Historic Trend Analysis (2020 to 2021)

4.1. Global Non-Insulin Therapies for Diabetes Market, 2020 – 2021 (US$ Million)

4.2. Global Non-Insulin Therapies for Diabetes Market, By Type, 2020 to 2021 (US$ Million)

4.3. Global Non-Insulin Therapies for Diabetes Market, By Route of Administration, 2020 to 2021 (US$ Million)

4.4. Global Non-Insulin Therapies for Diabetes Market, By Distribution Channel, 2020 to 2021 (US$ Million)

4.5. Global Non-Insulin Therapies for Diabetes Market, By Region, 2020 to 2021 (US$ Million)


5. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Type

5.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Type, 2022 & 2033

5.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Type, 2022 to 2033

5.2.1. Type_ Biguanides

5.2.2. Type_ Sulfonylureas

5.2.3. Type_ Thiazolidinedione’s

5.2.4. Type_ Alpha-Glucosidase Inhibitor

5.2.5. Type_ DPP-4 Inhibitors

5.2.6. Type_ GLP-1 Analogs

5.2.7. Type_ Sodium-glucose co-transporter-2 (SGLT2) inhibitors


6. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Route of Administration

6.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Route of Administration, 2022 & 2033

6.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Route of Administration, 2022 to 2033

6.2.1. Route of Administration_ Oral

6.2.2. Route of Administration_ Intramuscular


7. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Distribution Channel

7.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Distribution Channel, 2022 & 2033

7.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Distribution Channel, 2022 to 2033

7.2.1. Distribution Channel_ Retail Pharmacy

7.2.2. Distribution Channel_ Hospital Pharmacy

7.2.3. Distribution Channel_ Online Pharmacy


8. Global Non-Insulin Therapies for Diabetes Market Analysis and Forecast, by Region

8.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Region, 2022 & 2033

8.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Region, 2022 to 2033

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Middle East and Africa

8.2.5. Latin America


9. North America Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis

9.1. North America Non-Insulin Therapies for Diabetes Market Assessments & Key Findings

9.2. North America Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033

9.3. North America Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

9.3.1. By Type

9.3.2. By Route of Administration

9.3.3. By Distribution Channel

9.3.4. By Major Country

9.3.4.1. The U.S.

9.3.4.2. Canada


10. Europe Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis

10.1. Europe Non-Insulin Therapies for Diabetes Market Assessments & Key Findings

10.2. Europe Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033

10.3. Europe Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

10.3.1. By Type

10.3.2. By Route of Administration

10.3.3. By Distribution Channel

10.3.4. By Major Country

10.3.4.1. Germany

10.3.4.2. The U.K.

10.3.4.3. France

10.3.4.4. Italy

10.3.4.5. Spain

10.3.4.6. Rest of Europe (includes all other European countries)


11. Asia Pacific Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis

11.1. Asia Pacific Non-Insulin Therapies for Diabetes Market Assessments & Key Findings

11.2. Asia Pacific Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033

11.3. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

11.3.1. By Type

11.3.2. By Route of Administration

11.3.3. By Distribution Channel

11.3.4. By Major Country

11.3.4.1. China

11.3.4.2. Japan

11.3.4.3. India

11.3.4.4. ASEAN

11.3.4.5. South Korea

11.3.4.6. Rest of Asia Pacific (includes all other Asia Pacific countries)


12. Middle East & Africa Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis

12.1. Middle East & Africa Non-Insulin Therapies for Diabetes Market Assessments & Key Findings

12.2. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033

12.3. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

12.3.1. By Type

12.3.2. By Route of Administration

12.3.3. By Distribution Channel

12.3.4. By Major Country

12.3.4.1. GCC

12.3.4.2. South Africa

12.3.4.3. Egypt

12.3.4.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)


13. Latin America Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis

13.1. Latin America Market Assessments & Key Findings

13.2. Latin America Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033

13.3. Latin America Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

13.3.1. By Type

13.3.2. By Route of Administration

13.3.3. By Distribution Channel

13.3.4. By Major Country

13.3.4.1. Brazil

13.3.4.2. Mexico

13.3.4.3. Rest of Latin America (includes all other Latin America countries)


14. Competitive Landscape

14.1. Non-Insulin Therapies for Diabetes Market Revenue Share Analysis (%), by Major Players (2021)

14.2. Non-Insulin Therapies for Diabetes Market Competition Matrix, by Leading Players

14.3. Non-Insulin Therapies for Diabetes List of Emerging, Prominent and Leading Players

14.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.


15. Company Profiles

15.1. AstraZeneca

15.1.1. Company Overview & Insights

15.1.2. Financial Performance

15.1.3. Product / Service Portfolio

15.1.4. Geographical Footprint & Share

15.1.5. Strategic Initiatives & Key Developments

*Similar details would be provided for all the players mentioned below

15.2. Boehringer Ingelheim GmbH,

15.3. Bristol-Myers Squibb,

15.4. Eli Lilly and Company,

15.5. GlaxoSmithKline,

15.6. F. Hoffmann-La Roche Ltd.,

15.7. Janssen Pharmaceuticals,

15.8. Merck and Company,

15.9. Novartis AG,

15.10. Novo Nordisk,

15.11. Pfizer,

15.12. Sanofi Aventis,

15.13. GSK

15.14. INTARCIA THERAPEUTICS

15.15. JIANGSU HANSOH PHARMACEUTICAL

15.16. NOVO NORDISK

15.17. EMISPHERE

15.18. UNI-BIO SCIENCE GROUP

15.19. Takeda Pharmaceuticals

15.20. Others


16. Assumptions and Research Methodology

16.1. Data Mining

16.2. Secondary Research

16.3. Primary Research

16.4. Subject Matter Expert Advice

16.5. Quality Check

16.6. Final Review

16.7. Data Triangulation

16.8. Bottom-Up Approach

16.9. Top Down Approach

16.10. Research Flow

16.11. Key Insights from Industry Experts

16.12. Data Sources

16.13. Assumptions

16.14. Limitations


17. Conclusions and Recommendations

17.1. Key Research Findings and Conclusion

17.2. Key Insights & Recommendations from Analysts

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.


CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $4750

Only Four Thousand Seven Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5750

Only Five Thousand Seven Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $7750

Only Seven Thousand Seven Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI